spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Automated testing of pharmaceutical packaging

ZwickRoell


 Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.

The Zwick testing system is designed for combined compression and torsion tests and is based around a zwickiLine Z5.0TN table-top testing machine (Fmax 5 kN)with additional torsion drive (Fmax 20 Nm). Specimen feed is via the roboTest handling system plus autoEdition2 automation software; bottles, auto-injectors or insulin pens are transported from the associated magazine to the testing machine. Even bottles of different sizes can be accommodated. Aspecial alignment unit is incorporated to ensure exact positioning of the test axis, while precision load and torsion cells guarantee high test-result accuracy. In conjunction with the testXpert III testing software and the Extended Traceability option (as per FDA21 CFR Part 11), complete, non-manipulable documentation of the testing process is available.
phone +49 7305 100
email info@zwick.com
web www.zwick.com/medical
email August-Nagel-Strasse 11, 89079, ULM, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>


White Papers

Clinical Trial Labelling More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

4-6 December 2018, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 4 - 6 December 2018 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy will provide you with the latest advice for transforming innovative research to prosperous cell & gene therapy manufacturing.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement